Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK) (Q73112568)
Jump to navigation
Jump to search
scientific article published on 01 June 1999
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK) |
scientific article published on 01 June 1999 |
Statements
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK) (English)
J Bernhard
M Castiglione-Gertsch
S F Schmitz
B Thürlimann
R Morant
M F Fey
H Bonnefoi
A Goldhirsch